Last reviewed · How we verify

Fetroja (CEFIDEROCOL)

Shionogi · FDA-approved approved Small molecule Quality 65/100

Fetroja works by binding to penicillin-binding proteins on bacterial cell walls, inhibiting cell wall synthesis and ultimately leading to bacterial cell death.

Fetroja (Cefiderocol) is a cephalosporin antibacterial drug developed by Shionogi Inc. It is a small molecule that targets a wide range of Gram-negative bacterial infections, including urinary tract infections caused by Escherichia coli, Klebsiella, and Pseudomonas. Fetroja was FDA-approved in 2019 for various indications, including pyelonephritis and urinary tract infections. The commercial status of Fetroja is patented, with no generic manufacturers available. Key safety considerations include potential side effects such as infusion site reactions and increased risk of Clostridioides difficile infection.

At a glance

Generic nameCEFIDEROCOL
SponsorShionogi
Drug classCephalosporin Antibacterial
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved
First approval2019
Annual revenue300

Mechanism of action

FETROJA is an antibacterial drug [see Microbiology (12.4)].

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity
SEC EDGARRevenue + earnings